|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zaimy MA, Saffarzadeh N, Mohammadi A,
Pourghadamyari H, Izadi P, Sarli A, Moghaddam LK, Paschepari SR,
Azizi H, Torkamandi S and Tavakkoly-Bazzaz J: New methods in the
diagnosis of cancer and gene therapy of cancer based on
nanoparticles. Cancer Gene Ther. 24:233–243. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heidrich I, Deitert B, Werner S and Pantel
K: Liquid biopsy for monitoring of tumor dormancy and early
detection of disease recurrence in solid tumors. Cancer Metastasis
Rev. 42:161–182. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feinberg AP and Levchenko A: Epigenetics
as a mediator of plasticity in cancer. Science. 379:eaaw38352023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Biswas A and De S: Drivers of dynamic
intratumor heterogeneity and phenotypic plasticity. Am J Physiol
Cell Physiol. 320:C750–C760. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maley CC, Aktipis A, Graham TA, Sottoriva
A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta
KJ, et al: Classifying the evolutionary and ecological features of
neoplasms. Nat Rev Cancer. 17:605–619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim TK, Slominski RM, Pyza E, Kleszczynski
K, Tuckey RC, Reiter RJ, Holick MF and Slominski AT: Evolutionary
formation of melatonin and vitamin D in early life forms: Insects
take centre stage. Biol Rev Camb Philos Soc. 99:1772–1790. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Almeida Chuffa LG, Seiva FRF, Cucielo
MS, Silveira HS, Reiter RJ and Lupi LA: Mitochondrial functions and
melatonin: A tour of the reproductive cancers. Cell Mol Life Sci.
76:837–863. 2019. View Article : Google Scholar
|
|
9
|
Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu
DP and Li HB: Melatonin for the prevention and treatment of cancer.
Oncotarget. 8:39896–39921. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rafiyan M, Davoodvandi A, Reiter RJ,
Mansournia MA, Rasooli Manesh SM, Arabshahi V and Asemi Z:
Melatonin and cisplatin co-treatment against cancer: A mechanistic
review of their synergistic effects and melatonin's protective
actions. Pathol Res Pract. 253:1550312024. View Article : Google Scholar
|
|
11
|
Reiter RJ, Sharma R, Rosales-Corral S,
Manucha W, Chuffa LGA and Zuccari DAPC: Melatonin and pathological
cell interactions: mitochondrial glucose processing in cancer
cells. Int J Mol Sci. 22:124942021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koll L, Gül D, Elnouaem MI, Raslan H,
Ramadan OR, Knauer SK, Strieth S, Hagemann J, Stauber RH and Khamis
A: Exploiting vitamin D receptor and its ligands to target squamous
cell carcinomas of the head and neck. Int J Mol Sci. 24:46752023.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Hu W, Xue S, Chen Q, Jiang Y,
Zhang H and Zuo W: Vitamin D and lung cancer; association,
prevention, and treatment. Nutr Cancer. 73:2188–2200. 2021.
View Article : Google Scholar
|
|
14
|
You W, Liu X, Tang H, Lu B, Zhou Q, Li Y,
Chen M, Zhao J, Xu Y, Wang M, et al: Vitamin D status is associated
with immune checkpoint inhibitor efficacy and immune-related
adverse event severity in lung cancer patients: A prospective
cohort study. J Immunother. 46:236–243. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hassan HT, Eliopoulos A, Maurer HR and
Spandidos DA: Recombinant human GM-CSF enhances the
anti-proliferative activity of vitamin D in MCF-7 human breast
cancer clonogenic cells. Eur J Cancer. 28A:1588–1589. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeon SM and Shin EA: Exploring vitamin D
metabolism and function in cancer. Exp Mol Med. 50:1–14. 2018.
|
|
17
|
Bellerba F, Serrano D, Johansson H, Pozzi
C, Segata N, NabiNejad A, Piperni E, Gnagnarella P, Macis D,
Aristarco V, et al: Colorectal cancer, vitamin D and microbiota: A
double-blind phase II randomized trial (ColoViD) in colorectal
cancer patients. Neoplasia. 34:1008422022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cucielo MS, Cesário RC, Silveira HS,
Gaiotte LB, Dos Santos SAA, de Campos Zuccari DAP, Seiva FRF,
Reiter RJ and de Almeida Chuffa LG: Melatonin reverses the
warburg-type metabolism and reduces mitochondrial membrane
potential of ovarian cancer cells independent of MT1 receptor
activation. Molecules. 27:43502022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garland CF, Garland FC, Gorham ED, Lipkin
M, Newmark H, Mohr SB and Holick MF: The role of vitamin D in
cancer prevention. Am J Public Health. 96:252–261. 2006. View Article : Google Scholar
|
|
20
|
Zhang L, Wang S, Che X and Li X: Vitamin D
and lung cancer risk: A comprehensive review and meta-analysis.
Cell Physiol Biochem. 36:299–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao M, Wan J, Zeng K, Tong M, Lee AC,
Ding J and Chen Q: The reduction in circulating melatonin level may
contribute to the pathogenesis of ovarian cancer: A retrospective
study. J Cancer. 7:831–836. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reiter RJ, Sharma R, Ma Q, Rosales-Corral
S and Manucha W: Circadian and non-circadian melatonin: Influences
on glucose metabolism in cancer cells. J Curr Sci Technol.
10:85–98. 2020.
|
|
23
|
Cipolla-Neto J and Amaral FGD: Melatonin
as a hormone: New physiological and clinical insights. Endocr Rev.
39:990–1028. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Claustrat B and Leston J: Melatonin:
Physiological effects in humans. Neurochirurgie. 61:77–84. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Emet M, Ozcan H, Ozel L, Yayla M, Halici Z
and Hacimuftuoglu A: A review of melatonin, its receptors and
drugs. Eurasian J Med. 48:135–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Clough SJ, Hutchinson AJ,
Adamah-Biassi EB, Popovska-Gorevski M and Dubocovich ML: MT1 and
MT2 melatonin receptors: A therapeutic perspective. Annu Rev
Pharmacol Toxicol. 56:361–383. 2016. View Article : Google Scholar :
|
|
27
|
Ng KY, Leong MK, Liang H and Paxinos G:
Melatonin receptors: Distribution in mammalian brain and their
respective putative functions. Brain Struct Funct. 222:2921–2939.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cucielo MS, Freire PP, Emílio-Silva MT,
Romagnoli GG, Carvalho RF, Kaneno R, Hiruma-Lima CA, Delella FK,
Reiter RJ and Chuffa LGA: Melatonin enhances cell death and
suppresses the metastatic capacity of ovarian cancer cells by
attenuating the signaling of multiple kinases. Pathol Res Pract.
248:1546372023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Franco PIR, do Carmo Neto JR, Milhomem AC,
Machado JR and Miguel MP: Antitumor effect of melatonin on breast
cancer in experimental models: A systematic review. Biochim Biophys
Acta Rev Cancer. 1878:1888382023. View Article : Google Scholar
|
|
30
|
Tamtaji OR, Mirhosseini N, Reiter RJ,
Behnamfar M and Asemi Z: Melatonin and pancreatic cancer: Current
knowledge and future perspectives. J Cell Physiol. 234:5372–5378.
2019. View Article : Google Scholar
|
|
31
|
Slominski AT, Semak I, Fischer TW, Kim TK,
Kleszczyński K, Hardeland R and Reiter RJ: Metabolism of melatonin
in the skin: Why is it important? Exp Dermatol. 26:563–568. 2017.
View Article : Google Scholar :
|
|
32
|
Slominski AT, Zmijewski MA, Semak I, Kim
TK, Janjetovic Z, Slominski RM and Zmijewski JW: Melatonin,
mitochondria, and the skin. Cell Mol Life Sci. 74:3913–3925. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim KJ, Choi JS, Kang I, Kim KW, Jeong CH
and Jeong JW: Melatonin suppresses tumor progression by reducing
angiogenesis stimulated by HIF-1 in a mouse tumor model. J Pineal
Res. 54:264–270. 2013. View Article : Google Scholar
|
|
34
|
Stehle JH, von Gall C and Korf HW:
Melatonin: A clock-output, a clock-input. J Neuroendocrinol.
15:383–389. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Slominski RM, Reiter RJ,
Schlabritz-Loutsevitch N, Ostrom RS and Slominski AT: Melatonin
membrane receptors in peripheral tissues: Distribution and
functions. Mol Cell Endocrinol. 351:152–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stevens RG, Brainard GC, Blask DE, Lockley
SW and Motta ME: Breast cancer and circadian disruption from
electric lighting in the modern world. CA Cancer J Clin.
64:207–218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gaiotte LB, Cesário RC, Silveira HS, de
Morais Oliveira DA, Cucielo MS, Romagnoli GG, Kaneno R, de Campos
Zuccari AP, Reiter RJ and de Almeida Chuffa LG: Combination of
melatonin with paclitaxel reduces the TLR4-mediated inflammatory
pathway, PD-L1 levels, and survival of ovarian carcinoma cells.
Melatonin Res. 5:34–51. 2022. View Article : Google Scholar
|
|
38
|
Slominski RM, Raman C, Chen JY and
Slominski AT: How cancer hijacks the body's homeostasis through the
neuroendocrine system. Trends Neurosci. 46:263–275. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reiter RJ, Rosales-Corral SA, Tan DX,
Acuna-Castroviejo D, Qin L, Yang SF and Xu K: Melatonin, a full
service anti-cancer agent: Inhibition of initiation, progression
and metastasis. Int J Mol Sci. 18:8432017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Talib WH: Melatonin and cancer hallmarks.
Molecules. 23:5182018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Moloudizargari M, Moradkhani F, Hekmatirad
S, Fallah M, Asghari MH and Reiter RJ: Therapeutic targets of
cancer drugs: Modulation by melatonin. Life Sci. 267:1189342021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chuffa L, Carvalho R, Camargo VL, Cury S,
Domeniconi R, Zuccari DA and Seiva FR: Melatonin and cancer:
Exploring gene networks and functional categories. Melatonin Res.
6:431–451. 2023. View Article : Google Scholar
|
|
43
|
de Almeida Chuffa LG, Carvalho RF,
Justulin LA, Cury SS, Seiva FRF, Jardim-Perassi BV, Zuccari DAPC
and Reiter RJ: A meta-analysis of microRNA networks regulated by
melatonin in cancer: Portrait of potential candidates for breast
cancer treatment. J Pineal Res. 69:e126932020. View Article : Google Scholar
|
|
44
|
Ben-David U and Amon A: Context is
everything: Aneuploidy in cancer. Nat Rev Genet. 21:44–62. 2020.
View Article : Google Scholar
|
|
45
|
Bakhoum SF and Cantley LC: The
multifaceted role of chromosomal instability in cancer and its
microenvironment. Cell. 174:1347–1360. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
El-Missiry MA and Abd El-Aziz AF:
Influence of melatonin on proliferation and antioxidant system in
Ehrlich ascites carcinoma cells. Cancer Lett. 151:119–125. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Reiter RJ, Mayo JC, Tan DX, Sainz RM,
Alatorre-Jimenez M and Qin L: Melatonin as an antioxidant: Under
promises but over delivers. J Pineal Res. 61:253–278. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mir SM, Aliarab A, Goodarzi G, Shirzad M,
Jafari SM, Qujeq D, Samavarchi Tehrani S and Asadi J: Melatonin: A
smart molecule in the DNA repair system. Cell Biochem Funct.
40:4–16. 2022. View Article : Google Scholar
|
|
49
|
Galano A, Tan DX and Reiter RJ: Melatonin:
A versatile protector against oxidative DNA damage. Molecules.
23:5302018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Alonso-González C, González A,
Menéndez-Menéndez J, Martínez-Campa C and Cos S: Melatonin as a
radio-sensitizer in cancer. Biomedicines. 8:2472020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Esmaely F, Mahmoudzadeh A, Cheki M and
Shirazi A: The radioprotective effect of melatonin against
radiation-induced DNA double-strand breaks in radiology. J Cancer
Res Ther. 16(Suppl 1): S59–S63. 2020. View Article : Google Scholar
|
|
52
|
Farhood B, Goradel NH, Mortezaee K,
Khanlarkhani N, Salehi E, Nashtaei MS, Mirtavoos-Mahyari H,
Motevaseli E, Shabeeb D, Musa AE and Najafi M: Melatonin as an
adjuvant in radiotherapy for radioprotection and
radiosensitization. Clin Transl Oncol. 21:268–279. 2019. View Article : Google Scholar
|
|
53
|
Cos S, Recio J and Sánchez-Barceló EJ:
Modulation of the length of the cell cycle time of MCF-7 human
breast cancer cells by melatonin. Life Sci. 58:811–816. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cabrera J, Negrín G, Estévez F, Loro J,
Reiter RJ and Quintana J: Melatonin decreases cell proliferation
and induces melanogenesis in human melanoma SK-MEL-1 cells. J
Pineal Res. 49:45–54. 2010.PubMed/NCBI
|
|
55
|
Liu L, Zhu Y, Xu Y and Reiter RJ:
Melatonin delays cell proliferation by inducing G1 and G2/M phase
arrest in a human osteoblastic cell line hFOB 1.19. J Pineal Res.
50:222–231. 2011. View Article : Google Scholar
|
|
56
|
Martín V, Herrera F, Carrera-Gonzalez P,
García-Santos G, Antolín I, Rodriguez-Blanco J and Rodriguez C:
Intracellular signaling pathways involved in the cell growth
inhibition of glioma cells by melatonin. Cancer Res. 66:1081–1088.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Targhazeh N, Reiter RJ, Rahimi M, Qujeq D,
Yousefi T, Shahavi MH and Mir SM: Oncostatic activities of
melatonin: Roles in cell cycle, apoptosis, and autophagy.
Biochimie. 202:34–48. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shen CJ, Chang CC, Chen YT, Lai CS and Hsu
YC: Melatonin suppresses the growth of ovarian cancer cell lines
(OVCAR-429 and PA-1) and potentiates the effect of G1 arrest by
targeting CDKs. Int J Mol Sci. 17:1762016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pizarro JG, Yeste-Velasco M, Esparza JL,
Verdaguer E, Pallàs M, Camins A and Folch J: The antiproliferative
activity of melatonin in B65 rat dopaminergic neuroblastoma cells
is related to the downregulation of cell cycle-related genes. J
Pineal Res. 45:8–16. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Long F, Dong C, Jiang K, Xu Y, Chi X, Sun
D, Gao Z, Shao S and Wang L: Melatonin enhances the anti-tumor
effect of sorafenib via AKT/p27-mediated cell cycle arrest in
hepatocarcinoma cell lines†. RSC Adv. 7:21342–21351. 2017.
View Article : Google Scholar
|
|
61
|
Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee
H, Lee J and Kim SH: Melatonin sensitizes H1975 non-small-cell lung
cancer cells harboring a T790M-targeted epidermal growth factor
receptor mutation to the tyrosine kinase inhibitor gefitinib. Cell
Physiol Biochem. 34:865–872. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hong Y, Won J, Lee Y, Lee S, Park K, Chang
KT and Hong Y: Melatonin treatment induces interplay of apoptosis,
autophagy, and senescence in human colorectal cancer cells. J
Pineal Res. 56:264–274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu L, Xu Y and Reiter RJ: Melatonin
inhibits the proliferation of human osteosarcoma cell line MG-63.
Bone. 55:432–438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cini G, Neri B, Pacini A, Cesati V,
Sassoli C, Quattrone S, D'Apolito M, Fazio A, Scapagnini G,
Provenzani A and Quattrone A: Antiproliferative activity of
melatonin by transcriptional inhibition of cyclin D1 expression: A
molecular basis for melatonin-induced oncostatic effects. J Pineal
Res. 39:12–20. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen
LZ, Sheng H, Mo HY, Zeng JB, Deng W, et al: Melatonin overcomes
gemcitabine resistance in pancreatic ductal adenocarcinoma by
abrogating nuclear factor-κB activation. J Pineal Res. 60:27–38.
2016. View Article : Google Scholar
|
|
66
|
Margheri M, Pacini N, Tani A, Nosi D,
Squecco R, Dama A, Masala E, Francini F, Zecchi-Orlandini S and
Formigli L: Combined effects of melatonin and all-trans retinoic
acid and somatostatin on breast cancer cell proliferation and
death: Molecular basis for the anticancer effect of these
molecules. Eur J Pharmacol. 681:34–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Carbajo-Pescador S, Martín-Renedo J,
García-Palomo A, Tuñón MJ, Mauriz JL and González-Gallego J:
Changes in the expression of melatonin receptors induced by
melatonin treatment in hepatocarcinoma HepG2 cells. J Pineal Res.
47:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mediavilla MD, Cos S and Sánchez-Barceló
EJ: Melatonin increases p53 and p21WAF1 expression in MCF-7 human
breast cancer cells in vitro. Life Sci. 65:415–420. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
She MH, Chen BB, Wang XM and He SS:
p53-dependent antiproliferation and apoptosis of H22 cell induced
by melatonin. Ai Zheng. 23:803–807. 2004.In Chinese. PubMed/NCBI
|
|
70
|
Kim CH and Yoo YM: Melatonin induces
apoptotic cell death via p53 in LNCaP cells. Korean J Physiol
Pharmacol. 14:365–369. 2010. View Article : Google Scholar
|
|
71
|
Hong RT, Xu JM and Mei Q: Melatonin
ameliorates experimental hepatic fibrosis induced by carbon
tetrachloride in rats. World J Gastroenterol. 15:1452–1458. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chuffa LG, Alves MS, Martinez M, Camargo
IC, Pinheiro PF, Domeniconi RF, Júnior LA and Martinez FE:
Apoptosis is triggered by melatonin in an in vivo model of ovarian
carcinoma. Endocr Relat Cancer. 23:65–76. 2016. View Article : Google Scholar
|
|
73
|
Sánchez DI, González-Fernández B, Crespo
I, San-Miguel B, Álvarez M, González-Gallego J and Tuñón MJ:
Melatonin modulates dysregulated circadian clocks in mice with
diethylnitrosamine-induced hepatocellular carcinoma. J Pineal Res.
65:e125062018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bizzarri M, Proietti S, Cucina A and
Reiter RJ: Molecular mechanisms of the pro-apoptotic actions of
melatonin in cancer: A review. Expert Opin Ther Targets.
17:1483–1496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Carneiro BA and El-Deiry WS: Targeting
apoptosis in cancer therapy. Nat Rev Clin Oncol. 17:395–417. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Rubio S, Estévez F, Cabrera J, Reiter RJ,
Loro J and Quintana J: Inhibition of proliferation and induction of
apoptosis by melatonin in human myeloid HL-60 cells. J Pineal Res.
42:131–138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Leja-Szpak A, Jaworek J, Pierzchalski P
and Reiter RJ: Melatonin induces pro-apoptotic signaling pathway in
human pancreatic carcinoma cells (PANC-1). J Pineal Res.
49:248–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Xu L, Jin QD, Gong X, Liu H and Zhou RX:
Anti-gastric cancer effect of melatonin and Bcl-2, Bax, p21 and p53
expression changes. Sheng Li Xue Bao. 66:723–729. 2014.In Chinese.
PubMed/NCBI
|
|
79
|
Chuffa LGA, Reiter RJ and Lupi LA:
Melatonin as a promising agent to treat ovarian cancer: Molecular
mechanisms. Carcinogenesis. 38:945–952. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bock FJ and Tait SWG: Mitochondria as
multifaceted regulators of cell death. Nat Rev Mol Cell Biol.
21:85–100. 2020. View Article : Google Scholar
|
|
81
|
Tian C, Liu Y, Li Z, Zhu P and Zhao M:
Mitochondria related cell death modalities and disease. Front Cell
Dev Biol. 10:8323562022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Bejarano I, Redondo PC, Espino J, Rosado
JA, Paredes SD, Barriga C, Reiter RJ, Pariente JA and Rodríguez AB:
Melatonin induces mitochondrial-mediated apoptosis in human myeloid
HL-60 cells. J Pineal Res. 46:392–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Trubiani O, Recchioni R, Moroni F,
Pizzicannella J, Caputi S and Di Primio R: Melatonin provokes cell
death in human B-lymphoma cells by mitochondrial-dependent
apoptotic pathway activation. J Pineal Res. 39:425–431. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Joo SS and Yoo YM: Melatonin induces
apoptotic death in LNCaP cells via p38 and JNK pathways:
Therapeutic implications for prostate cancer. J Pineal Res.
47:8–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Carbajo-Pescador S, Steinmetz C, Kashyap
A, Lorenz S, Mauriz JL, Heise M, Galle PR, González-Gallego J and
Strand S: Melatonin induces transcriptional regulation of Bim by
FoxO3a in HepG2 cells. Br J Cancer. 108:442–449. 2013. View Article : Google Scholar :
|
|
86
|
Fan L, Sun G, Ma T, Zhong F and Wei W:
Melatonin overcomes apoptosis resistance in human hepatocellular
carcinoma by targeting survivin and XIAP. J Pineal Res. 55:174–183.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Verma P, Rishi B, George NG, Kushwaha N,
Dhandha H, Kaur M, Jain A, Jain A, Chaudhry S, Singh A, et al:
Recent advances and future directions in etiopathogenesis and
mechanisms of reactive oxygen species in cancer treatment. Pathol
Oncol Res. 29:16114152023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Huang R, Chen H, Liang J, Li Y, Yang J,
Luo C, Tang Y, Ding Y, Liu X, Yuan Q, et al: Dual role of reactive
oxygen species and their application in cancer therapy. J Cancer.
12:5543–5561. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Florido J, Martinez-Ruiz L,
Rodriguez-Santana C, López-Rodríguez A, Hidalgo-Gutiérrez A,
Cottet-Rousselle C, Lamarche F, Schlattner U, Guerra-Librero A,
Aranda-Martínez P, et al: Melatonin drives apoptosis in head and
neck cancer by increasing mitochondrial ROS generated via reverse
electron transport. J Pineal Res. 73:e128242022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Florido J, Rodriguez-Santana C,
Martinez-Ruiz L, López-Rodríguez A, Acuña-Castroviejo D, Rusanova I
and Escames G: Understanding the mechanism of action of melatonin,
which induces ROS production in cancer cells. Antioxidants (Basel).
11:16212022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Li M, Wu C, Muhammad JS, Yan D, Tsuneyama
K, Hatta H, Cui ZG and Inadera H: Melatonin sensitises
shikonin-induced cancer cell death mediated by oxidative stress via
inhibition of the SIRT3/SOD2-AKT pathway. Redox Biol.
36:1016322020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Chen X, Hao B, Li D, Reiter RJ, Bai Y,
Abay B, Chen G, Lin S, Zheng T, Ren Y, et al: Melatonin inhibits
lung cancer development by reversing the Warburg effect via
stimulating the SIRT3/PDH axis. J Pineal Res. 71:e127552021.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Reiter RJ, Sharma R, Rodriguez C, Martin
V, Rosales-Corral S, Zuccari DAPC and Chuffa LGA: Part-time cancers
and role of melatonin in determining their metabolic phenotype.
Life Sci. 278:1195972021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Park SY, Jang WJ, Yi EY, Jang JY, Jung Y,
Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by
inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res.
48:178–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Reiter RJ, Sharma R, Ma Q, Rorsales-Corral
S and de Almeida Chuffa LG: Melatonin inhibits Warburg-dependent
cancer by redirecting glucose oxidation to the mitochondria: A
mechanistic hypothesis. Cell Mol Life Sci. 77:2527–2542. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chuffa LGA, Fioruci-Fontanelli BA, Mendes
LO, Ferreira Seiva FR, Martinez M, Fávaro WJ, Domeniconi RF,
Pinheiro PF, Delazari Dos Santos L and Martinez FE: Melatonin
attenuates the TLR4-mediated inflammatory response through MyD88-
and TRIF-dependent signaling pathways in an in vivo model of
ovarian cancer. BMC Cancer. 15:342015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lu JJ, Fu L, Tang Z, Zhang C, Qin L, Wang
J, Yu Z, Shi D, Xiao X, Xie F, et al: Melatonin inhibits
AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C
signaling to enhance the antitumor activity of berberine in lung
cancer cells. Oncotarget. 7:2985–3001. 2016. View Article : Google Scholar
|
|
98
|
Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu
L, Liu L, Xie F, Kang T, Huang W and Deng W: Simultaneous
modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin
to inhibit proliferation and induce apoptosis in breast cancer
cells. J Pineal Res. 53:77–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chuang JI, Mohan N, Meltz ML and Reiter
RJ: Effect of melatonin on NF-kappa-B DNA-binding activity in the
rat spleen. Cell Biol Int. 20:687–692. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Niranjan R, Nath C and Shukla R: The
mechanism of action of MPTP-induced neuroinflammation and its
modulation by melatonin in rat astrocytoma cells, C6. Free Radic
Res. 44:1304–1316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Schito L: Hypoxia-dependent angiogenesis
and lymphangiogenesis in cancer. Adv Exp Med Biol. 1136:71–85.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Colombo J, Maciel JMW, Ferreira LC, DA
Silva RF and Zuccari DAP: Effects of melatonin on HIF-1α and VEGF
expression and on the invasive properties of hepatocarcinoma cells.
Oncol Lett. 12:231–237. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Jardim-Perassi BV, Arbab AS, Ferreira LC,
Borin TF, Varma NR, Iskander AS, Shankar A, Ali MM and de Campos
Zuccari DA: Effect of melatonin on tumor growth and angiogenesis in
xenograft model of breast cancer. PLoS One. 9:e853112014.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zonta YR, Martinez M, Camargo ICC,
Domeniconi RF, Lupi Júnior LAL, Pinheiro PFF, Reiter RJ, Martinez
FE and Chuffa LGA: Melatonin reduces angiogenesis in serous
papillary ovarian carcinoma of ethanol-preferring rats. Int J Mol
Sci. 18:7632017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ma Q, Reiter RJ and Chen Y: Role of
melatonin in controlling angiogenesis under physiological and
pathological conditions. Angiogenesis. 23:91–104. 2020. View Article : Google Scholar
|
|
107
|
Sulekha Suresh D and Guruvayoorappan C:
Molecular principles of tissue invasion and metastasis. Am J
Physiol Cell Physiol. 324:C971–C991. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Tang H, Shi X, Zhu P, Guo W, Li J, Yan B
and Zhang S: Melatonin inhibits gallbladder cancer cell migration
and invasion via ERK-mediated induction of
epithelial-to-mesenchymal transition. Oncol Lett. 22:6092021.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang X, Wang B, Xie J, Hou D, Zhang H and
Huang H: Melatonin inhibits epithelial-to-mesenchymal transition in
gastric cancer cells via attenuation of IL-1β/NF-κB/MMP2/MMP9
signaling. Int J Mol Med. 42:2221–2228. 2018.PubMed/NCBI
|
|
111
|
Wang X, Wang B, Zhan W, Kang L, Zhang S,
Chen C, Hou D, You R and Huang H: Melatonin inhibits lung
metastasis of gastric cancer in vivo. Biomed Pharmacother.
117:1090182019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhou Q, Gui S, Zhou Q and Wang Y:
Melatonin inhibits the migration of human lung adenocarcinoma A549
cell lines involving JNK/MAPK pathway. PLoS One. 9:e1011322014.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Cos S, Fernández R, Güézmes A and
Sánchez-Barceló EJ: Influence of melatonin on invasive and
metastatic properties of MCF-7 human breast cancer cells. Cancer
Res. 58:4383–4390. 1998.PubMed/NCBI
|
|
114
|
Tai HC, Wang SW, Swain S, Lin LW, Tsai HC,
Liu SC, Wu HC, Guo JH, Liu CL, Lai YW, et al: Melatonin suppresses
the metastatic potential of osteoblastic prostate cancers by
inhibiting integrin α2 β1 expression. J
Pineal Res. 72:e127932022. View Article : Google Scholar
|
|
115
|
Xu CS, Wang ZF, Huang XD, Dai LM, Cao CJ
and Li ZQ: Involvement of ROS-alpha v beta 3 integrin-FAK/Pyk2 in
the inhibitory effect of melatonin on U251 glioma cell migration
and invasion under hypoxia. J Transl Med. 13:952015. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Najafi M, Farhood B and Mortezaee K:
Extracellular matrix (ECM) stiffness and degradation as cancer
drivers. J Cell Biochem. 120:2782–2790. 2019. View Article : Google Scholar
|
|
117
|
Nguyen BT, Lin CY, Chang TK, Fong YC,
Thadevoos LA, Lai CY, Huang YL, Tsai CH, Ko CY, Liu JF, et al:
Melatonin inhibits chondrosarcoma cell proliferation and metastasis
by enhancing miR-520f-3p production and suppressing MMP7
expression. J Pineal Res. 75:e128722023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Liu D, Shi K, Fu M and Chen F: Melatonin
indirectly decreases gastric cancer cell proliferation and invasion
via effects on cancer-associated fibroblasts. Life Sci.
277:1194972021. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Ordoñez R, Carbajo-Pescador S,
Prieto-Dominguez N, García-Palomo A, González-Gallego J and Mauriz
JL: Inhibition of matrix metalloproteinase-9 and nuclear factor
kappa B contribute to melatonin prevention of motility and
invasiveness in HepG2 liver cancer cells. J Pineal Res. 56:20–30.
2014. View Article : Google Scholar
|
|
120
|
Akbarzadeh M, Movassaghpour AA, Ghanbari
H, Kheirandish M, Fathi Maroufi N, Rahbarghazi R, Nouri M and
Samadi N: The potential therapeutic effect of melatonin on human
ovarian cancer by inhibition of invasion and migration of cancer
stem cells. Sci Rep. 7:170622017. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Lin YW, Lee LM, Lee WJ, Chu CY, Tan P,
Yang YC, Chen WY, Yang SF, Hsiao M and Chien MH: Melatonin inhibits
MMP-9 transactivation and renal cell carcinoma metastasis by
suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity. J
Pineal Res. 60:277–290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Doğanlar O, Doğanlar ZB, Delen E and Doğan
A: The role of melatonin in angio-miR-associated inhibition of
tumorigenesis and invasion in human glioblastoma tumour spheroids.
Tissue Cell. 73:1016172021. View Article : Google Scholar
|
|
123
|
Chen YT, Yang CC, Shao PL, Huang CR and
Yip HK: Melatonin-mediated downregulation of ZNF746 suppresses
bladder tumorigenesis mainly through inhibiting the AKT-MMP-9
signaling pathway. J Pineal Res. 66:e125362019. View Article : Google Scholar
|
|
124
|
Mills E, Wu P, Seely D and Guyatt G:
Melatonin in the treatment of cancer: A systematic review of
randomized controlled trials and meta-analysis. J Pineal Res.
39:360–366. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Seely D, Wu P, Fritz H, Kennedy DA, Tsui
T, Seely AJ and Mills E: Melatonin as adjuvant cancer care with and
without chemotherapy: A systematic review and meta-analysis of
randomized trials. Integr Cancer Ther. 11:293–303. 2012. View Article : Google Scholar
|
|
126
|
Favero G, Moretti E, Bonomini F, Reiter
RJ, Rodella LF and Rezzani R: Promising antineoplastic actions of
melatonin. Front Pharmacol. 9:10862018. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Oz E, Erbaş D, Sürücü HS and Düzgün E:
Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol
Cell Biochem. 282:31–37. 2006. View Article : Google Scholar
|
|
128
|
Lissoni P, Barni S, Mandalà M, Ardizzoia
A, Paolorossi F, Vaghi M, Longarini R, Malugani F and Tancini G:
Decreased toxicity and increased efficacy of cancer chemotherapy
using the pineal hormone melatonin in metastatic solid tumour
patients with poor clinical status. Eur J Cancer. 35:1688–1692.
1999. View Article : Google Scholar
|
|
129
|
Talib WH, Alsayed AR, Abuawad A, Daoud S
and Mahmod AI: Melatonin in cancer treatment: Current knowledge and
future opportunities. Molecules. 26:25062021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Bouillon R, Manousaki D, Rosen C,
Trajanoska K, Rivadeneira F and Richards JB: The health effects of
vitamin D supplementation: Evidence from human studies. Nat Rev
Endocrinol. 18:96–110. 2022. View Article : Google Scholar
|
|
131
|
Carlberg C: Vitamin D in the context of
evolution. Nutrients. 14:30182022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Holick MF, Mazzei L, García Menéndez S,
Martín Giménez VM, Al Anouti F and Manucha W: Genomic or
non-genomic? A question about the pleiotropic roles of vitamin D in
inflammatory-based diseases. Nutrients. 15:7672023. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Khazai N, Judd SE and Tangpricha V:
Calcium and vitamin D: Skeletal and extraskeletal health. Curr
Rheumatol Rep. 10:110–117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Martín Giménez VM, Lahore H, Ferder L,
Holick MF and Manucha W: The little-explored therapeutic potential
of nanoformulations of 1,25-dihydroxyvitamin D3 and its
active analogs in prevalent inflammatory and oxidative disorders.
Nanomedicine (Lond). 16:2327–2330. 2021. View Article : Google Scholar
|
|
135
|
Mazzaferro S, Goldsmith D, Larsson TE,
Massy ZA and Cozzolino M: Vitamin D metabolites and/or analogs:
Which D for which patient? Curr Vasc Pharmacol. 12:339–349. 2014.
View Article : Google Scholar
|
|
136
|
Ysmail-Dahlouk L, Nouari W and Aribi M:
1,25-Dihydroxyvitamin D3 down-modulates the production
of proinflammatory cytokines and nitric oxide and enhances the
phosphorylation of monocyte-expressed STAT6 at the recent-onset
type 1 diabetes. Immunol Lett. 179:122–130. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Slominski AT, Kim TK, Shehabi HZ, Tang EK,
Benson HA, Semak I, Lin Z, Yates CR, Wang J, Li W and Tuckey RC: In
vivo production of novel vitamin D2 hydroxy-derivatives by human
placentas, epidermal keratinocytes, Caco-2 colon cells and the
adrenal gland. Mol Cell Endocrinol. 383:181–192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Christakos S, Dhawan P, Verstuyf A,
Verlinden L and Carmeliet G: Vitamin D: Metabolism, molecular
mechanism of action, and pleiotropic effects. Physiol Rev.
96:365–408. 2016. View Article : Google Scholar :
|
|
139
|
Jones G, Strugnell SA and DeLuca HF:
Current understanding of the molecular actions of vitamin D.
Physiol Rev. 78:1193–1231. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
van den Heuvel EG, Lips P, Schoonmade LJ,
Lanham-New SA and van Schoor NM: Comparison of the effect of daily
vitamin D2 and vitamin D3 supplementation on serum
25-hydroxyvitamin D concentration (total 25(OH)D, 25(OH)D2, and
25(OH) D3) and importance of body mass index: A systematic review
and meta-analysis. Adv Nutr. 15:1001332024. View Article : Google Scholar
|
|
141
|
Haussler MR, Haussler CA, Jurutka PW,
Thompson PD, Hsieh JC, Remus LS, Selznick SH and Whitfield GK: The
vitamin D hormone and its nuclear receptor: Molecular actions and
disease states. J Endocrinol. 154(Suppl 1): S57–S73.
1997.PubMed/NCBI
|
|
142
|
Norlin M and Wikvall K: Enzymatic
activation in vitamin D signaling-past, present and future. Arch
Biochem Biophys. 742:1096392023. View Article : Google Scholar
|
|
143
|
Araya Z, Hosseinpour F, Bodin K and
Wikvall K: Metabolism of 25-hydroxyvitamin D3 by microsomal and
mitochondrial vitamin D3 25-hydroxylases (CYP2D25 and CYP27A1): A
novel reaction by CYP27A1. Biochim Biophys Acta. 1632:40–47. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Kaseda R, Hosojima M, Sato H and Saito A:
Role of megalin and cubilin in the metabolism of vitamin D(3). Ther
Apher Dial. 15(Suppl 1): S14–S17. 2011. View Article : Google Scholar
|
|
145
|
Slominski AT, Kim TK, Shehabi HZ, Semak I,
Tang EK, Nguyen MN, Benson HA, Korik E, Janjetovic Z, Chen J, et
al: In vivo evidence for a novel pathway of vitamin D3
metabolism initiated by P450scc and modified by CYP27B1. FASEB J.
26:3901–3915. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Slominski AT, Kim TK, Janjetovic Z,
Slominski RM, Li W, Jetten AM, Indra AK, Mason RS and Tuckey RC:
Biological effects of CYP11A1-derived vitamin D and lumisterol
metabolites in the skin. J Invest Dermatol. 144:2145–2161. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Qayyum S, Slominski RM, Raman C and
Slominski AT: Novel CYP11A1-derived vitamin D and lumisterol
biometabolites for the management of COVID-19. Nutrients.
14:47792022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Slominski AT, Kim TK, Li W, Postlethwaite
A, Tieu EW, Tang EKY and Tuckey RC: Detection of novel
CYP11A1-derived secosteroids in the human epidermis and serum and
pig adrenal gland. Sci Rep. 5:148752015. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Slominski AT, Li W, Kim TK, Semak I, Wang
J, Zjawiony JK and Tuckey RC: Novel activities of CYP11A1 and their
potential physiological significance. J Steroid Biochem Mol Biol.
151:25–37. 2015. View Article : Google Scholar
|
|
150
|
McLeod JF and Cooke NE: The vitamin
D-binding protein, alpha-fetoprotein, albumin multigene family:
Detection of transcripts in multiple tissues. J Biol Chem.
264:21760–21769. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Girgis CM and Brennan-Speranza TC: Vitamin
D and skeletal muscle: Current concepts from preclinical studies.
JBMR Plus. 5:e105752021. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Park CY and Han SN: The role of vitamin D
in adipose tissue biology: Adipocyte differentiation, energy
metabolism, and inflammation. J Lipid Atheroscler. 10:130–144.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Sempos CT, Heijboer AC, Bikle DD,
Bollerslev J, Bouillon R, Brannon PM, DeLuca HF, Jones G, Munns CF,
Bilezikian JP, et al: Vitamin D assays and the definition of
hypovitaminosis D: Results from the first international conference
on controversies in vitamin D. Br J Clin Pharmacol. 84:2194–2207.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Bouillon R, Schuit F, Antonio L and
Rastinejad F: Vitamin D binding protein: A historic overview. Front
Endocrinol (Lausanne). 10:9102020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Deeb KK, Trump DL and Johnson CS: Vitamin
D signalling pathways in cancer: Potential for anticancer
therapeutics. Nat Rev Cancer. 7:684–700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Nezbedova P and Brtko J:
1alpha,25-dihydroxyvitamin D3 inducible transcription factor and
its role in the vitamin D action. Endocr Regul. 38:29–38.
2004.PubMed/NCBI
|
|
157
|
Falzone L, Gattuso G, Candido S, Tomaselli
A, Fagone S, Spandidos DA and Libra M: Vitamin D and microRNAs:
Role in the pathogenesis and prognosis of breast cancer (Review).
Int J Epigenetics. 3:52023. View Article : Google Scholar
|
|
158
|
Fleet JC, DeSmet M, Johnson R and Li Y:
Vitamin D and cancer: A review of molecular mechanisms. Biochem J.
441:61–76. 2012. View Article : Google Scholar
|
|
159
|
Slominski AT, Chaiprasongsuk A, Janjetovic
Z, Kim TK, Stefan J, Slominski RM, Hanumanthu VS, Raman C, Qayyum
S, Song Y, et al: Photoprotective properties of vitamin D and
lumisterol hydroxyderivatives. Cell Biochem Biophys. 78:165–180.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Slominski AT, Kim TK, Janjetovic Z,
Brożyna AA, Żmijewski MA, Xu H, Sutter TR, Tuckey RC, Jetten AM and
Crossman DK: Differential and overlapping effects of
20,23(OH)2D3 and 1,25(OH)2D3 on gene
expression in human epidermal keratinocytes: Identification of AhR
as an alternative receptor for 20,23(OH)2D3. Int J Mol
Sci. 19:30722018. View Article : Google Scholar
|
|
161
|
Slominski AT, Kim TK, Qayyum S, Song Y,
Janjetovic Z, Oak ASW, Slominski RM, Raman C, Stefan J,
Mier-Aguilar CA, et al: Vitamin D and lumisterol derivatives can
act on liver X receptors (LXRs). Sci Rep. 11:80022021. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Slominski AT, Kim TK, Slominski RM, Song
Y, Janjetovic Z, Podgorska E, Reddy SB, Song Y, Raman C, Tang EKY,
et al: Metabolic activation of tachysterol3 to
biologically active hydroxyderivatives that act on VDR, AhR, LXRs,
and PPARγ receptors. Faseb J. 36:e224512022. View Article : Google Scholar
|
|
163
|
Song Y, Slominski RM, Qayyum S, Kim TK,
Janjetovic Z, Raman C, Tuckey RC, Song Y and Slominski AT:
Molecular and structural basis of interactions of vitamin D3
hydroxyderivatives with aryl hydrocarbon receptor (AhR): An
integrated experimental and computational study. Int J Biol
Macromol. 209:1111–1123. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Escriva H, Bertrand S and Laudet V: The
evolution of the nuclear receptor superfamily. Essays Biochem.
40:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Gil Á, Plaza-Diaz J and Mesa MD: Vitamin
D: Classic and novel actions. Ann Nutr Metab. 72:87–95. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Flach KD and Zwart W: The first decade of
estrogen receptor cistromics in breast cancer. J Endocrinol.
229:R43–R56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Meyer MB and Pike JW: Corepressors (NCoR
and SMRT) as well as coactivators are recruited to positively
regulated 1α,25-dihydroxyvitamin D3-responsive genes. J Steroid
Biochem Mol Biol. 136:120–124. 2013. View Article : Google Scholar
|
|
168
|
Negri M, Gentile A, de Angelis C, Montò T,
Patalano R, Colao A, Pivonello R and Pivonello C: Vitamin D-induced
molecular mechanisms to potentiate cancer therapy and to reverse
drug-resistance in cancer cells. Nutrients. 12:17982020. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Starska-Kowarska K: Role of vitamin D in
head and neck cancer-immune function, anti-tumour effect, and its
impact on patient prognosis. Nutrients. 15:25922023. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Bhoora S and Punchoo R: Policing cancer:
Vitamin D arrests the cell cycle. Int J Mol Sci. 21:92962020.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Shariev A, Painter N, Reeve VE, Haass NK,
Rybchyn MS, Ince FA, Mason RS and Dixon KM: PTEN: A novel target
for vitamin D in melanoma. J Steroid Biochem Mol Biol.
218:1060592022. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Varghese JE, Shanmugam V, Rengarajan RL,
Meyyazhagan A, Arumugam VA, Al-Misned FA and El-Serehy HA: Role of
vitamin D3 on apoptosis and inflammatory-associated gene 528 in
colorectal cancer: An in vitro approach. J King Saud Univ Sci.
32:2786–2789. 2020. View Article : Google Scholar
|
|
173
|
Seraphin G, Rieger S, Hewison M,
Capobianco E and Lisse TS: The impact of vitamin D on cancer: A
mini review. J Steroid Biochem Mol Biol. 231:1063082023. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Samuel S and Sitrin MD: Vitamin D's role
in cell proliferation and differentiation. Nutr Rev. 66(Suppl 2):
S116–S124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Fernández-Barral A, Bustamante-Madrid P,
Ferrer-Mayorga G, Barbáchano A, Larriba MJ and Muñoz A: Vitamin D
effects on cell differentiation and stemness in cancer. Cancers
(Basel). 12:24132020. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Bajbouj K, Al-Ali A, Shafarin J, Sahnoon
L, Sawan A, Shehada A, Elkhalifa W, Saber-Ayad M, Muhammad JS,
Elmoselhi AB, et al: Vitamin D exerts significant antitumor effects
by suppressing vasculogenic mimicry in breast cancer cells. Front
Oncol. 12:9183402022. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Kalkunte S, Brard L, Granai CO and Swamy
N: Inhibition of angiogenesis by vitamin D-binding protein:
Characterization of anti-endothelial activity of DBP-maf.
Angiogenesis. 8:349–360. 2005. View Article : Google Scholar
|
|
178
|
Liu W, Zhang L, Xu HJ, Li Y, Hu CM, Yang
JY and Sun MY: The anti-inflammatory effects of vitamin D in
tumorigenesis. Int J Mol Sci. 19:27362018. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
El-Sharkawy A and Malki A: Vitamin D
signaling in inflammation and cancer: Molecular mechanisms and
therapeutic implications. Molecules. 25:32192020. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Liu J, Shen J, Mu C, Liu Y, He D, Luo H,
Wu W, Zheng X, Liu Y, Chen S, et al: High-dose vitamin D metabolite
delivery inhibits breast cancer metastasis. Bioeng Transl Med.
7:e102632021. View Article : Google Scholar
|
|
181
|
Zhuravel E, Efanova O, Shestakova T,
Glushko N, Mezhuev O, Soldatkina M and Pogrebnoy P: Administration
of vitamin D3 improves antimetastatic efficacy of cancer vaccine
therapy of Lewis lung carcinoma. Exp Oncol. 32:33–39.
2010.PubMed/NCBI
|
|
182
|
Zmijewski MA: Vitamin D and human health.
Int J Mol Sci. 20:1452019. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Hii CS and Ferrante A: The non-genomic
actions of vitamin D. Nutrients. 8:1352016. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Levin ER: Rapid signaling by steroid
receptors. Am J Physiol Regul Integr Comp Physiol. 295:R1425–R1430.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Doroudi M, Schwartz Z and Boyan BD:
Membrane-mediated actions of 1,25-dihydroxy vitamin D3: A review of
the roles of phospholipase A2 activating protein and
Ca(2+)/calmodulin-dependent protein kinase II. J Steroid Biochem
Mol Biol. 147:81–84. 2015. View Article : Google Scholar
|
|
186
|
Sirajudeen S, Shah I and Al Menhali A: A
Narrative role of vitamin d and its receptor: With current evidence
on the gastric tissues. Int J Mol Sci. 20:38322019. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Lajdova I, Spustova V, Oksa A, Kaderjakova
Z, Chorvat D Jr, Morvova M Jr, Sikurova L and Marcek Chorvatova A:
The impact of vitamin D3 supplementation on mechanisms of cell
calcium signaling in chronic kidney disease. Biomed Res Int.
2015:8076732015. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Sergeev IN: Calcium signaling in cancer
and vitamin D. J Steroid Biochem Mol Biol. 97:145–151. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Norman AW: Minireview: Vitamin D receptor:
New assignments for an already busy receptor. Endocrinology.
147:5542–5548. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Mantell DJ, Owens PE, Bundred NJ, Mawer EB
and Canfield AE: 1 alpha,25-dihydroxyvitamin D(3) inhibits
angiogenesis in vitro and in vivo. Circ Res. 87:214–220. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Jamali N, Sorenson CM and Sheibani N:
Vitamin D and regulation of vascular cell function. Am J Physiol
Heart Circ Physiol. 314:H753–H765. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Wu X, Hu W, Lu L, Zhao Y, Zhou Y, Xiao Z,
Zhang L, Zhang H, Li X, Li W, et al: Repurposing vitamin D for
treatment of human malignancies via targeting tumor
microenvironment. Acta Pharm Sin B. 9:203–219. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Santos JM, Khan ZS, Munir MT, Tarafdar K,
Rahman SM and Hussain F: Vitamin D3 decreases glycolysis
and invasiveness, and increases cellular stiffness in breast cancer
cells. J Nutr Biochem. 53:111–120. 2018. View Article : Google Scholar
|
|
194
|
Corachán A, Ferrero H, Escrig J, Monleon
J, Faus A, Cervelló I and Pellicer A: Long-term vitamin D treatment
decreases human uterine leiomyoma size in a xenograft animal model.
Fertil Steril. 113:205–216.e4. 2020. View Article : Google Scholar
|
|
195
|
Karkeni E, Morin SO, Bou Tayeh B, Goubard
A, Josselin E, Castellano R, Fauriat C, Guittard G, Olive D and
Nunès JA: Vitamin D controls tumor growth and CD8+ T cell
infiltration in breast cancer. Front Immunol. 10:13072019.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Veeresh PKM, Basavaraju CG, Dallavalasa S,
Anantharaju PG, Natraj SM, Sukocheva OA and Madhunapantula SV:
Vitamin D3 inhibits the viability of breast cancer cells in vitro
and ehrlich ascites carcinomas in mice by promoting apoptosis and
cell cycle arrest and by impeding tumor angiogenesis. Cancers
(Basel). 15:48332023. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Welsh J: Vitamin D and breast cancer:
Insights from animal models. Am J Clin Nutr. 80(Suppl 6):
1721S–1724S. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Li J, Luco AL, Camirand A, St-Arnaud R and
Kremer R: Vitamin D regulates CXCL12/CXCR4 and
epithelial-to-mesenchymal transition in a model of breast cancer
metastasis to lung. Endocrinology. 162:bqab0492021. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Reid C, Flores-Villalva S, Remot A,
Kennedy E, O'Farrelly C and Meade KG: Long-term in vivo vitamin
D3 supplementation modulates bovine IL-1 and chemokine
responses. Sci Rep. 13:108462023. View Article : Google Scholar
|
|
200
|
Muñoz A and Grant WB: Vitamin D and
cancer: An historical overview of the epidemiology and mechanisms.
Nutrients. 14:14482022. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Chandler PD, Chen WY, Ajala ON, Hazra A,
Cook N, Bubes V, Lee IM, Giovannucci EL, Willett W, Buring JE, et
al: Effect of vitamin D3 supplements on development of advanced
cancer: A secondary analysis of the VITAL randomized clinical
trial. JAMA Netw Open. 3:e20258502020. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Keum N, Lee DH, Greenwood DC, Manson JE
and Giovannucci E: Vitamin D supplementation and total cancer
incidence and mortality: A meta-analysis of randomized controlled
trials. Ann Oncol. 30:733–743. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Talib WH, Ahmed Jum'AH DA, Attallah ZS,
Jallad MS, Al Kury LT, Hadi RW and Mahmod AI: Role of vitamins A,
C, D, E in cancer prevention and therapy: Therapeutic potentials
and mechanisms of action. Front Nutr. 10:12818792024. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
El-Bassiouny NA, Helmy MW, Hassan MAE and
Khedr GA: The Cardioprotective effect of vitamin D in breast cancer
patients receiving adjuvant doxorubicin based chemotherapy. Clin
Breast Cancer. 22:359–366. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Galus Ł, Michalak M, Lorenz M,
Stoińska-Swiniarek R, Tusień Małecka D, Galus A, Kolenda T,
Leporowska E and Mackiewicz J: Vitamin D supplementation increases
objective response rate and prolongs progression-free time in
patients with advanced melanoma undergoing anti-PD-1 therapy.
Cancer. 129:2047–2055. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Yu X, Liu B, Zhang N, Wang Q and Cheng G:
Immune response: A missed opportunity between vitamin D and
radiotherapy. Front Cell Dev Biol. 9:6469812021. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Arayici ME, Basbinar Y and Ellidokuz H:
Vitamin D intake, serum 25-hydroxyvitamin-D (25(OH)D) levels, and
cancer risk: A comprehensive meta-meta-analysis including
meta-analyses of randomized controlled trials and observational
epidemiological studies. Nutrients. 15:27222023. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Krasanakis T, Nikolouzakis TK, Sgantzos M,
Mariolis-Sapsakos T, Souglakos J, Spandidos DA, Tsitsimpikou C,
Tsatsakis A and Tsiaoussis J: Role of anabolic agents in colorectal
carcinogenesis: Myths and realities (Review). Oncol Rep.
42:2228–2244. 2019.PubMed/NCBI
|
|
209
|
Dimitrakopoulou VI, Tsilidis KK, Haycock
PC, Dimou NL, Al-Dabhani K, Martin RM, Lewis SJ, Gunter MJ, Mondul
A, Shui IM, et al: Circulating vitamin D concentration and risk of
seven cancers: Mendelian randomisation study. BMJ. 359:j47612017.
View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Young MRI and Xiong Y: Influence of
vitamin D on cancer risk and treatment: Why the variability? Trends
Cancer Res. 13:43–53. 2018.PubMed/NCBI
|
|
211
|
Mocayar Marón FJ, Ferder L, Reiter RJ and
Manucha W: Daily and seasonal mitochondrial protection: Unraveling
common possible mechanisms involving vitamin D and melatonin. J
Steroid Biochem Mol Biol. 199:1055952020. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Vitti-Ruela BV, Dokkedal-Silva V, Hachul
H, Tufik S and Andersen ML: Melatonin and vitamin D: Complementary
therapeutic strategies for breast cancer. Support Care Cancer.
29:3433–3434. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Bizzarri M, Cucina A, Valente MG,
Tagliaferri F, Borrelli V, Stipa F and Cavallaro A: Melatonin and
vitamin D3 increase TGF-beta1 release and induce growth inhibition
in breast cancer cell cultures. J Surg Res. 110:332–337. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Proietti S, Cucina A, D'Anselmi F,
Dinicola S, Pasqualato A, Lisi E and Bizzarri M: Melatonin and
vitamin D3 synergistically down-regulate Akt and MDM2 leading to
TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal
Res. 50:150–158. 2011. View Article : Google Scholar
|
|
215
|
Wang H, Wei W, Wang NP, Gui SY, Wu L, Sun
WY and Xu SY: Melatonin ameliorates carbon tetrachloride-induced
hepatic fibrogenesis in rats via inhibition of oxidative stress.
Life Sci. 77:1902–1915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Özerkan D, Özsoy N and Yılmaz E: Vitamin D
and melatonin protect the cell's viability and ameliorate the CCl4
induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines.
Cytotechnology. 67:995–1002. 2015. View Article : Google Scholar
|
|
217
|
Frenkel M, Abrams DI, Ladas EJ, Deng G,
Hardy M, Capodice JL, Winegardner MF, Gubili JK, Yeung KS, Kussmann
H and Block KI: Integrating dietary supplements into cancer care.
Integr Cancer Ther. 12:369–384. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Nuszkiewicz J, Czuczejko J, Maruszak M,
Pawłowska M, Woźniak A, Małkowski B and Szewczyk-Golec K:
Parameters of oxidative stress, vitamin D, osteopontin, and
melatonin in patients with lip, oral cavity, and pharyngeal cancer.
Oxid Med Cell Longev. 2021:23649312021. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Rai V, Bose S, Saha S and Chakraborty C:
Evaluation of oxidative stress and the microenvironment in oral
submucous fibrosis. Heliyon. 5:e015022019. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Di Bella G: The Di Bella Method (DBM)
improved survival, objective response and performance status in a
retrospective observational clinical study on 122 cases of breast
cancer. Neuro Endocrinol Lett. 32:751–762. 2011.PubMed/NCBI
|
|
221
|
Di Bella G and Colori B: The Di Bella
Method (DBM) improved survival, objective response and performance
status in a retrospective observational clinical study on 23
tumours of the head and neck. Neuro Endocrinol Lett. 33:249–256.
2012.PubMed/NCBI
|
|
222
|
Di Bella G, Borghetto V and Costanzo E: A
retrospective observational study on cases of anaplastic brain
tumors treated with the Di Bella Method: A rationale and
effectiveness. Neuro Endocrinol Lett. 42:464–483. 2021.
|
|
223
|
Di Bella G, Di Bella L, Borghetto V,
Moscato I and Costanzo E: A retrospective observational study on
cases of osteosarcomas treated with a multitherapy: The rationale
and effectiveness. Neuro Endocrinol Lett. 43:173–179.
2022.PubMed/NCBI
|
|
224
|
Norsa A and Martino V: Somatostatin,
retinoids, melatonin, vitamin D, bromocriptine, and
cyclophosphamide in advanced non-small-cell lung cancer patients
with low performance status. Cancer Biother Radiopharm. 21:68–73.
2006.PubMed/NCBI
|
|
225
|
Norsa A and Martino V: Somatostatin,
retinoids, melatonin, vitamin D, bromocriptine, and
cyclophosphamide in chemotherapy-pretreated patients with advanced
lung adenocarcinoma and low performance status. Cancer Biother
Radiopharm. 22:50–55. 2007.PubMed/NCBI
|
|
226
|
Nuszkiewicz J, Woźniak A and
Szewczyk-Golec K: Ionizing radiation as a source of oxidative
stress-the protective role of melatonin and vitamin D. Int J Mol
Sci. 21:58042020. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Minich DM, Henning M, Darley C, Fahoum M,
Schuler CB and Frame J: Is Melatonin the 'Next vitamin D'?: A
review of emerging science, clinical uses, safety, and dietary
supplements. Nutrients. 14:39342022. View Article : Google Scholar
|
|
228
|
Smolensky MH, Sackett-Lundeen LL and
Portaluppi F: Nocturnal light pollution and underexposure to
daytime sunlight: Complementary mechanisms of circadian disruption
and related diseases. Chronobiol Int. 32:1029–1048. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Besedovsky L, Lange T and Haack M: The
sleep-immune crosstalk in health and disease. Physiol Rev.
99:1325–1380. 2019. View Article : Google Scholar : PubMed/NCBI
|
